SCHEMBL18657307

SCHEMBL18657307

C=CCc1cccc(N)c1OC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 1/20 0.43
ADRA2B P18089 1/20 0.43
ADRA2C P18825 1/20 0.43
GABRA1 P14867 3/20 0.42
GABRB2 P47870 3/20 0.42
CYP3A4 P08684 2/20 0.41
ALOX15 P16050 2/20 0.41
ALDH1A1 P00352 6/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
TP53 P04637 1/20 0.39
TSHR P16473 1/20 0.39
ALOX12 P18054 1/20 0.39
ELANE P08246 1/20 0.39
KDM4E B2RXH2 1/20 0.38
DHFR P00374 1/20 0.37
MAPT P10636 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
AKR1B1 P15121 1/20 0.36
MEN1 O00255 1/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL44672 0.87 GABRA1 (0.48) ADRA2AADRA2BADRA2CGABRA1GABRB2
SCHEMBL13256543 0.82 GABRA1 (0.42) ADRA2AADRA2BADRA2CGABRA1GABRB2
SCHEMBL3460333 0.80 ALDH1A1 (0.52) CYP3A4ALOX15ALDH1A1SMN1; SMN2TSHR
SCHEMBL30681592 0.80 ALDH1A1 (0.52) CYP3A4ALOX15ALDH1A1SMN1; SMN2TSHR
SCHEMBL2215565 0.79 ALDH1A1 (0.41) ADRA2BCYP3A4ALDH1A1SMN1; SMN2TSHR
SCHEMBL23020587 0.79 CYP3A4 (0.44) ADRA2AADRA2BADRA2CGABRA1GABRB2
SCHEMBL3739900 0.79 GABRA1 (0.50) ADRA2AADRA2BADRA2CGABRA1GABRB2
SCHEMBL11145612 0.79 GABRA1 (0.42) ADRA2AADRA2BADRA2CGABRA1GABRB2
SCHEMBL7263878 0.79 ALDH1A1 (0.45) ADRA2AADRA2BADRA2CGABRA1GABRB2
SCHEMBL10071057 0.77 CYP3A4 (0.43) ADRA2AADRA2BADRA2CGABRA1GABRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2393794-B1 DESIGN, SYNTHESIS AND EVALUATION OF PROCASPASE ACTIVATING COMPOUNDS AS PERSONALIZED ANTI-CANCER DRUGS UNIV ILLINOIS (US) 2017-03-22 EP disclosed